Related Experiment Videos
Glucocorticoid osteoporosis
I R Reid1, A G Veale, J T France
1Department of Medicine, University of Auckland, New Zealand.
Abstract:
Glucocorticoids act on calcium metabolism at many levels to produce osteoporosis, the major pathogenic effect probably being an inhibition of bone formation. In men, this is likely to be contributed to by a dose-related reduction in circulating testosterone concentrations. Bone density is reduced 10-20% at the commonly assessed sites, but deficits of twice this magnitude are found in trabecular bone. Dose and duration of steroid treatment influence the degree of osteopenia, but biochemical indexes of calcium metabolism are not predictive. In managing a steroid-treated patient, bone densitometry is usually helpful. Those with low densities should optimize their calcium intake, and those with sex hormone deficiency should receive appropriate replacement therapy. If bone loss is severe or continues despite these measures, the addition of bisphosphonate, calcitonin, fluoride, or a vitamin D metabolite may be appropriate, according to local availability. Thiazide diuretics can be combined with all these regimens. If thiazide diuretics are combined with vitamin D or its metabolites, careful monitoring of serum calcium should be undertaken. Bone density should be monitored annually until it is stable.
Insights
Glucocorticoids can cause osteoporosis by inhibiting bone formation and reducing testosterone. Bone density loss is significant, especially in trabecular bone, requiring monitoring and interventions like calcium, hormone replacement, or medications.
Area of Science:
- Endocrinology
- Metabolic Bone Disease
Background:
- Glucocorticoids significantly impact calcium metabolism, leading to osteoporosis.
- A primary mechanism involves the inhibition of bone formation.
- In men, reduced testosterone levels contribute to glucocorticoid-induced bone loss.
Purpose of the Study:
- To outline the effects of glucocorticoids on calcium metabolism and bone health.
- To discuss the clinical management of glucocorticoid-induced osteoporosis.
- To highlight the role of bone densitometry and therapeutic interventions.
Main Methods:
- Review of the literature on glucocorticoid effects on bone metabolism.
- Analysis of factors influencing bone density reduction.
- Discussion of diagnostic and therapeutic strategies for managing osteoporosis.
Main Results:
- Glucocorticoid treatment reduces bone density by 10-20% at assessed sites, with greater deficits in trabecular bone.
- Dose and duration of steroid therapy correlate with osteopenia severity.
- Biochemical markers of calcium metabolism are not reliable predictors of bone loss.
Conclusions:
- Bone densitometry is crucial for managing patients on steroid therapy.
- Optimizing calcium intake and hormone replacement are initial management steps.
- Bisphosphonates, calcitonin, fluoride, or vitamin D metabolites may be added for severe bone loss, with thiazide diuretics as an adjunct therapy.